{"name":"Galapagos NV","slug":"galapagos","ticker":"GLPG","exchange":"NASDAQ","domain":"glpg.com","description":"Galapagos NV is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.","hq":"Mechelen, Belgium","founded":0,"employees":"","ceo":"Paul Stoffels","sector":"Inflammation / Fibrosis / Cell Therapy","stockPrice":27.73,"stockChange":0,"stockChangePercent":0,"marketCap":"$2.2B","metrics":{"revenue":1219193977.4255998,"revenueGrowth":-91.4,"grossMargin":54,"rdSpend":0,"netIncome":569946257.6865023,"cash":3483518160.672,"dividendYield":0,"peRatio":3.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"filgotinib patent cliff ($1.4B at risk)","drug":"filgotinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"GLPG2451 dose regimen A","genericName":"GLPG2451 dose regimen A","slug":"glpg2451-dose-regimen-a","indication":"Other","status":"phase_1"},{"name":"GLPG1972","genericName":"GLPG1972","slug":"glpg1972","indication":"Other","status":"phase_2"},{"name":"GLPG2222 50 mg","genericName":"GLPG2222 50 mg","slug":"glpg2222-50-mg","indication":"Other","status":"phase_2"},{"name":"[14C]-GLPG3667 solution for infusion","genericName":"[14C]-GLPG3667 solution for infusion","slug":"14c-glpg3667-solution-for-infusion","indication":"Other","status":"phase_1"},{"name":"Cocktail of CYP450 substrates","genericName":"Cocktail of CYP450 substrates","slug":"cocktail-of-cyp450-substrates","indication":"Other","status":"phase_1"},{"name":"GLPG0259 free base","genericName":"GLPG0259 free base","slug":"glpg0259-free-base","indication":"Other","status":"phase_1"},{"name":"GLPG0974","genericName":"GLPG0974","slug":"glpg0974","indication":"Other","status":"phase_2"},{"name":"GLPG1205","genericName":"GLPG1205","slug":"glpg1205","indication":"Other","status":"phase_2"},{"name":"GLPG1837 multiple ascending doses","genericName":"GLPG1837 multiple ascending doses","slug":"glpg1837-multiple-ascending-doses","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"GLPG2451 dose regimen A","genericName":"GLPG2451 dose regimen A","slug":"glpg2451-dose-regimen-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GLPG1972","genericName":"GLPG1972","slug":"glpg1972","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GLPG2222 50 mg","genericName":"GLPG2222 50 mg","slug":"glpg2222-50-mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-GLPG3667 solution for infusion","genericName":"[14C]-GLPG3667 solution for infusion","slug":"14c-glpg3667-solution-for-infusion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cocktail of CYP450 substrates","genericName":"Cocktail of CYP450 substrates","slug":"cocktail-of-cyp450-substrates","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GLPG0259 free base","genericName":"GLPG0259 free base","slug":"glpg0259-free-base","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GLPG0974","genericName":"GLPG0974","slug":"glpg0974","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GLPG1205","genericName":"GLPG1205","slug":"glpg1205","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GLPG1837 multiple ascending doses","genericName":"GLPG1837 multiple ascending doses","slug":"glpg1837-multiple-ascending-doses","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"earnings","headline":"Galapagos NV Reports Fourth Quarter and Full Year 2022 Results","summary":"Galapagos NV reported its fourth quarter and full year 2022 results, with revenue of $1.4 billion and a net loss of $1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2022-12-20","type":"deal","headline":"Galapagos NV and Gilead Sciences Announce Collaboration to Develop and Commercialize Filgotinib in Japan","summary":"Galapagos NV and Gilead Sciences announced a collaboration to develop and commercialize filgotinib in Japan.","drugName":"","sentiment":"positive"},{"date":"2022-09-01","type":"regulatory","headline":"Galapagos NV Receives FDA Approval for Jyseleca (filgotinib) in Ulcerative Colitis","summary":"Galapagos NV received FDA approval for Jyseleca (filgotinib) in ulcerative colitis.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: 20-F","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2026-03-24","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-17","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-19","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPS3llSkxRYlRqazVVRmNrSjBTRFBpOGN1TnBJdkRkbXFEX2NVNERxUklXSEFNSVRFV0c3bGRvaFNHSV9zWUtkdGFMdXM4d2dsb1NjZUd1ZWI4VFRBVW9nb29VZVZtbngtd2pYd0hvTldwM19FVXl3R1l3eEhvdlJRRlFMazZ6VnFLQmE1QmUyREFtY1RxUXM0VkV1b3p2NFFLY0xuQjdfZE9ZWkdNTVg3Q09zYnRqSGh1d2VqWVY1NHpvNjBTeVFudV8yY1FDZThQYjlnWFQxVDI?oc=5","date":"2026-01-05","type":"pipeline","source":"Stocktwits","summary":"Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction - Stocktwits","headline":"Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction","sentiment":"neutral"},{"date":"2026-01-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"}],"patents":[{"drugName":"filgotinib","drugSlug":"filgotinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":9,"phaseCounts":{"phase_1":5,"phase_2":4},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","AbbVie","Roche Holding"],"therapeuticFocus":["Inflammation","Fibrosis","Cell Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":1299203319.3744,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":1299203319.3744},{"period":"2024-12-31","value":321982233.98219997},{"period":"2023-12-31","value":280018679.7672},{"period":"2022-12-31","value":281800013.6622}],"grossProfit":1264469060.5535998,"grossProfitHistory":[{"period":"2025-12-31","value":1264469060.5535998},{"period":"2024-12-31","value":281259189.0108},{"period":"2023-12-31","value":280018679.7672},{"period":"2022-12-31","value":281800013.6622}],"rdSpend":536644065.16379994,"rdSpendHistory":[{"period":"2025-12-31","value":536644065.16379994},{"period":"2024-12-31","value":391845565.3002},{"period":"2023-12-31","value":281852577.61319995},{"period":"2022-12-31","value":315146584.1766}],"sgaSpend":130779110.08799998,"operatingIncome":585668710.1298,"operatingIncomeHistory":[{"period":"2025-12-31","value":585668710.1298},{"period":"2024-12-31","value":-219995320.07639998},{"period":"2023-12-31","value":-103098933.49139999},{"period":"2022-12-31","value":-153086082.8046}],"netIncome":374820685.6152,"netIncomeHistory":[{"period":"2025-12-31","value":374820685.6152},{"period":"2024-12-31","value":86534280.3996},{"period":"2023-12-31","value":247280682.99659997},{"period":"2022-12-31","value":-254632627.60979998}],"eps":4.87,"epsHistory":[{"period":"2025-12-31","value":4.87},{"period":"2024-12-31","value":1.12},{"period":"2023-12-31","value":3.21},{"period":"2022-12-31","value":-3.32}],"cash":102637538.8104,"cashHistory":[{"period":"2025-12-31","value":102637538.8104},{"period":"2024-12-31","value":75036792.18419999},{"period":"2023-12-31","value":194840549.30339998},{"period":"2022-12-31","value":593525268.6725999}],"totalAssets":3979112116.2804,"totalLiabilities":199334183.07,"totalDebt":8077327.136999999,"equity":3779777933.2103996,"operatingCashflow":-300731212.6368,"operatingCashflowHistory":[{"period":"2025-12-31","value":-300731212.6368},{"period":"2024-12-31","value":-373818466.28279996},{"period":"2023-12-31","value":-474208604.16599995},{"period":"2022-12-31","value":-584679339.7631999}],"capex":-16188528.820199998,"capexHistory":[{"period":"2025-12-31","value":-16188528.820199998},{"period":"2024-12-31","value":-95911689.25799999},{"period":"2023-12-31","value":-22512556.1694},{"period":"2022-12-31","value":-43157339.9466}],"freeCashflow":-316919741.45699996,"dividendsPaid":null,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":41472957.338999994,"ebit":-74410697.12339999,"ebitda":-74410697.12339999,"period":"2026-03-31","revenue":7570377.031799999,"epsBasic":0.22,"netIncome":16927928.3976,"rdExpense":36166334.463599995,"epsDiluted":0.22,"grossProfit":1964723.6796,"operatingIncome":-74410697.12339999},{"sga":3437682.3954,"ebit":654707371.461,"ebitda":654707371.461,"period":"2025-12-31","revenue":1052239188.1715999,"epsBasic":null,"netIncome":913615200.4187999,"rdExpense":125583455.55359998,"epsDiluted":null,"grossProfit":1051707708.2225999,"operatingIncome":886342686.4643999},{"sga":54226139.939399995,"ebit":2825604.3882,"ebitda":2825604.3882,"period":"2025-09-30","revenue":83122295.93579999,"epsBasic":null,"netIncome":-236083393.34579998,"rdExpense":86300662.8396,"epsDiluted":null,"grossProfit":70453215.65699999,"operatingIncome":-48676554.801599994},{"sga":21956546.376599997,"ebit":-118114702.16039999,"ebitda":-118114702.16039999,"period":"2025-06-30","revenue":76262116.28639999,"epsBasic":null,"netIncome":-123522948.67439999,"rdExpense":111289565.145,"epsDiluted":null,"grossProfit":70765095.09959999,"operatingIncome":-66612542.970599994},{"sga":51158741.3766,"ebit":-185384878.56239998,"ebitda":-185384878.56239998,"period":"2025-03-31","revenue":87579718.9806,"epsBasic":-2.33,"netIncome":-179188172.7834,"rdExpense":213470381.62559998,"epsDiluted":-2.33,"grossProfit":71543041.5744,"operatingIncome":-185384878.56239998},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":27.73,"previousClose":0,"fiftyTwoWeekHigh":37.78,"fiftyTwoWeekLow":25.98,"fiftyTwoWeekRange":"25.98 - 37.78","fiftyDayAverage":29.87,"twoHundredDayAverage":32.06,"beta":0,"enterpriseValue":-1276140220.063104,"forwardPE":-26.6,"priceToBook":9.57,"priceToSales":1.78,"enterpriseToRevenue":-1.05,"enterpriseToEbitda":-1.65,"pegRatio":0,"ebitda":774391376.218944,"ebitdaMargin":63.5,"freeCashflow":246432062.53754878,"operatingCashflow":-352294121.73690236,"totalDebt":7516644.993,"debtToEquity":0.2,"currentRatio":30.48,"returnOnAssets":10.7,"returnOnEquity":16.3,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":27.83,"targetHighPrice":27.83,"targetLowPrice":27.83,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":25.4,"institutionHeldPercent":22.3,"sharesOutstanding":65897071,"floatShares":44522059,"sharesShort":1371531,"shortRatio":6.95,"shortPercentOfFloat":2.1,"epsTrailing":8.71,"epsForward":-1.04,"revenuePerShare":0.79,"bookValue":2.9,"officers":[{"age":null,"name":"Mr. Henry  Gosebruch","title":"CEO & Executive Director"},{"age":41,"name":"Mr. Aaron L. Cox","title":"Chief Financial Officer"},{"age":null,"name":"Dr. Glenn  Schulman M.P.H., Pharm. D., Pharm.D.","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Fred W. Blakeslee II","title":"Executive VP & General Counsel"},{"age":null,"name":"Marieke  Vermeersch","title":"Head of Corporate Communication"},{"age":53,"name":"Ms. Tania  Philipp","title":"Chief Human Resources Officer"},{"age":null,"name":"Ms. Ellen Van Der Aar","title":"Head of Development"},{"age":52,"name":"Ms. Annelies  Missotten","title":"Executive Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.glpg.com","phone":"32 1 534 29 00"}}